Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the sodium glucose cotransporter 2 (sglt2) inhibitors market grown in recent years?
In recent times, the sodium glucose cotransporter 2 (SGLT2) inhibitors market has experienced robust growth. The market size is projected to escalate from $10.17 billion in 2024 to $11.07 billion in 2025, with a compound annual growth rate (CAGR) of 8.8%. This surge during the historic period has been fueled by successful early clinical trials, a rise in regulatory approvals, a growing rate of diabetes diagnoses, and the need for innovative treatments for diabetes.
How is the sodium glucose cotransporter 2 (sglt2) inhibitors market size expected to evolve during the forecast period?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $15.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing obesity rates, growing awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Major trends in the forecast period include the integration of combination therapies, personalized medicine approaches, technological improvement, and traditional drug development.
Get your sodium glucose cotransporter 2 (sglt2) inhibitors market report here!
Which key drivers are propelling the sodium glucose cotransporter 2 (sglt2) inhibitors market’s growth?
The escalating occurrence of diabetes is anticipated to drive the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes is a collection of metabolic diseases distinguished by elevated blood sugar levels due to problems with insulin secretion, insulin function, or both. The growth in diabetes instances can be linked to factors like urbanization, stress, environmental contaminants, and lack of healthcare access. Sodium glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels in diabetes patients by inhibiting glucose reabsorption in the kidneys, leading to its excretion through urine. These inhibitors also provide cardiac and renal advantages, making them an effective tool for managing diabetes and its associated complications. For example, the Australian Bureau of Statistics reported in December 2023 that in 2022, approximately 1.3 million people, or 5.3% of Australians, were diagnosed with diabetes, with similar rates in males (5.8%) and females (4.9%). The prevalence of diabetes has been continually rising, especially among those aged 75 and older, reaching 18.7%. The most prevalent type is Type 2 diabetes, responsible for 87.6% of cases. Factors like being born overseas, living in underprivileged areas, and having a disability are often linked with higher rates of diabetes. Therefore, the growing occurrence of diabetes is progressing the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.
What are the market segments in the sodium glucose cotransporter 2 (sglt2) inhibitors industry?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
Who are the dominant players expanding their reach in the sodium glucose cotransporter 2 (sglt2) inhibitors market?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.
What are the key trends shaping the future of the sodium glucose cotransporter 2 (sglt2) inhibitors market?
Leading companies in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are turning their attention to the development of dual inhibitor treatments for better patient results and blood sugar control. Such therapeutic solutions are designed to target two distinct sodium-glucose cotransporters (SGLT1 and SGLT2) concurrently, thus increasing their effectiveness in handling conditions like heart failure and diabetes. For example, Lexicon Pharmaceuticals Inc., an American biopharmaceutical firm, obtained approval for sotagliflozin, a heart failure treatment, from the Food and Drug Administration (FDA) in May 2023. This unique first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 comes in the form of a daily tablet. It aims to lower cardiovascular death, hospitalizations due to heart failure, and urgent visits for heart failure in adults suffering from heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risks. The drug offers decreased renal glucose and sodium reabsorption, resulting in reduced preload and afterload and lower sympathetic activity.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473
What regions are dominating the sodium glucose cotransporter 2 (sglt2) inhibitors market growth?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Sodium Benzoate Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/sodium-benzoate-global-market-report
Sodium Lauryl Ether Sulfate [SLES] Global Market Report 2024
Sodium Cocoyl Isethionate Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/sodium-cocoyl-isethionate-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
